东诚药业：子公司蓝纳成于2024年12月20日完成股改

Core Viewpoint - Dongcheng Pharmaceutical's subsidiary, Lanacheng, completed its share reform on December 20, 2024, and submitted its application for an initial public offering on the Hong Kong Stock Exchange on September 29, 2025 [2] Group 1 - The share reform of Lanacheng was finalized on December 20, 2024 [2] - The application for the IPO on the Hong Kong Stock Exchange was submitted on September 29, 2025 [2] - Relevant announcements were disclosed on the company's official information platform [2]